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‘‘Oncogene addiction’’ refers to the process of tumor cell death that can occur after inactivation of a single
oncogene. In this issue of Cancer Cell, Rakhra et al. argue that complete tumor clearance after molecular tar-
geted therapies requires a functioning immune system, pointing the way toward radically new combination
therapies.Tumor cells generally contain many ge-
netic and epigenetic abnormalities that
trigger manifold cellular pathways leading
to the uncontrolled growth and metas-
tases of transformed cells. Given the com-
plex disruption of the cancer genome and
epigenome, it may seem surprising that
the inactivation of a few or even one sin-
gle oncogene can profoundly affect the
maintenance and growth of a tumor cell
mass. Yet this perplexing phenomenon
often occurs and has been referred to as
‘‘oncogene addiction.’’
Oncogene addiction provides the ratio-
nale for molecularly targeted therapies,
which have substantially been validated
in both mice and in humans with cancer.
In a transgenic mouse system employing
a tetracycline regulatable c-Myc, the
withdrawal of this oncogene can lead to
sudden tumor cell death (Felsher and
Bishop, 1999). Another example is the
withdrawal of Oct3/4 in a mouse model
of choriocarcinoma (Gidekel et al., 2003).
Examples that this is a ‘‘real’’ phenom-
enon in patients with cancer comes from
treatments using monoclonal antibodies
such trastuzumab (Herceptin), which tar-
gets the HER2 receptor tyrosine kinase
in patients with HER2-positive breast
cancer. Small molecule drugs like imatinib
(Gleevec) can also interfere with the
functioning of various oncogenic protein
kinases by targeting the BCR-ABL in
chronic myeloid leukemia and KIT in
gastrointestinal stromal tumors. Erlotinib
(Tarceva) and gefitinib (Iressa) both tar-
get the epidermal growth factor receptor
(EGFR) and have some activities in varie-
ties of cancers. Melanoma patients can
be successfully treated with PLX4032,
an inhibitor of the serine–threonine pro-
tein kinase B-RAF, which disrupts themitogen-activated protein (MAP) kinase
pathway (Flaherty et al., 2010). In addition,
a subgroup of patients with non-small cell
lung cancers expressing an oncogenic
fusion of the EML4 and anaplastic lym-
phoma kinase (ALK) genes can be suc-
cessfully treated with crizotinib, a small
molecule inhibitor of the ALK tyrosine
kinase (Kwak et al., 2010).
Although these treatments are gener-
ally not curative, the striking effectiveness
of some single-agent inhibitors of onco-
genic proteins in humans and in animal
models has led to the quest to understand
the mechanisms underlying the phe-
nomena of oncogene addiction (Figure 1).
The partial or complete tumor regression
associated with oncogene withdrawal is
accompanied by cell cycle arrest, tumor
cell differentiation, senescence, and apo-
ptosis (Kaelin, 2005). While the precise
mechanisms involved remain largely
speculative, several theories have been
forwarded. Cancer cells accumulate mu-
tations resulting from various types of
genetic damage including polyploidy,
aneuploidy, endoreduplication (duplica-
tion of the genome without mitosis), DNA
breaks, translocations, and all of the
epigenetic abnormalities that accompany
these problems. Continued survival of
cancer cells is achieved only when they
acquire mutations that are neutral (‘‘pas-
senger’’) or beneficial (‘‘driver’’). In the
cumulative mutation or ‘‘house of cards’’
model, some of these alterations might
be lethal in the absence of preceding
mutations, so removing the activity of an
early oncogene enables programmed
death to occur (Figure 1A). Another theory
purports that a single oncogenic signaling
pathway comes to dominate over the
others because its efficiency results inCancer Cell 18, Na diminishing of selection pressure on
other pathways to maintain collateral sig-
naling pathways (Figure 1B). This ‘‘domi-
nant oncogene’’ theory requires the rapid
decay of these collateral growth fac-
tor signaling pathways. In yet a third
theory, dubbed ‘‘oncogene amnesia,’’
the removal of the dominant oncogene
enables the reinstatement of normal phy-
siologic programs, whereby a tumor
becomes subject to checkpoint-induced
apoptosis (Felsher, 2008) (Figure 1C).
This hypothesis takes as an assumption
that the original pathways controlling
cellular death are at least partially intact
after being subjected to the oncogenic
process.
Most theories regarding these phe-
nomena have assumed that onco-
gene addiction involves cell autonomous
mechanisms, but in this issue of Cancer
Cell, Rakhra et al. argue in favor of amech-
anism that is not entirely cell autonomous
(Rakhra et al., 2010). By doing experi-
ments using a series of immune-deficient
animals, the authors trace the key
immune cells to be CD4+ T cells. The
authors focus on the role of thrombo-
spondin-1 (TSP1), a pleiotropic glycopro-
tein that is produced by many cells,
including immune cells and platelets, and
has major roles in angiogenesis, inflam-
mation, and wound healing. Although
a more fulsome investigation of the roles
of CD4+ T cells will undoubtedly be forth-
coming, the cells are known to play a
central role in orchestrating many ele-
ments of the adaptive immune system
(Muranski and Restifo, 2009). CD4+
T cells accomplish this by direct interac-
tion with other immune cells and by pro-
ducing immunomodulatory cytokines and
chemokines. CD4+ T cells can activateovember 16, 2010 ª2010 Elsevier Inc. 403
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Figure 1. Theories of Oncogene Addiction
(A) In the ‘‘cumulative mutations’’ model, tumors accrue mutated oncogenes, some of which are ‘‘driver’’
and some of which are ‘‘passenger.’’ Any change must be neutral or beneficial to the tumor cell’s viability.
However, some mutations could occur that are beneficial only in the context of existing mutations but are
otherwise harmful. Withdrawal of an early oncogene signal in this scenario would induce senescence or
death, like a molecular ‘‘house of cards.’’
(B) In the ‘‘dominant oncogene’’ model, tumors receive signals from multiple growth factor pathways but
become dependent on one. With time, other cell growth pathways become less subject to selection and
suffer mutations or epigenetic changes that attenuate or obliterate their functions. Removal of the domi-
nant growth factor signal then triggers apoptosis. Note that arrows represent intracellular signaling path-
ways.
(C) The ‘‘oncogene amnesia’’ model. Intact oncogene signal (shown at left) limits cell death; thus, path-
ways that would normally induce senescence and death are held in check by the activities of the onco-
gene, but are reinstated upon withdrawal of the oncogene’s activity (shown at right).
(D) How mechanisms of immune activation might explain oncogene addiction. When cells experience
apoptosis associated with inactivation of an oncogene, they might release tumor-associated antigens,
which come in the form of tissue differentiation antigens, cancer/testis antigens, or products of mutated
genes expressed by the transformed cells. Additional immune activating signals including calreticulin, the
S100 family of proteins, and (in secondary necrosis) the highmobility group box 1 protein (HMGB1) can be
emitted by some dying cells. Resulting activation of host antigen presenting cells (APC) could in turn acti-
vate CD4+ T cells capable of producing a host of immunoregulatory and antiangiogenesis molecules,
including thrombospondin-1 (TSP1). CD4+ T cells recognizing processed tumor-associated antigens
also can activate CD8+ T cells and natural killer (NK) cells, leading to more tumor killing. The activities
of immune cells can be inhibited by myeloid-derived suppressor cells (MDSC) and by regulatory T cells
(Tregs). However, the administration of tumor-reactive T cells in combination with ablation of regulatory
cells can result in long-term durable tumor regression in mice and humans.
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CD8+ T cells and natural killer (NK) cells,
whose activities can be inhibited by
myeloid-derived suppressor cells (MDSC)
and by regulatory T cells (Tregs). When
given in combination with antitumor
T cells, ablation of these immunoregula-404 Cancer Cell 18, November 16, 2010 ª20tory cells can enable complete and
durable tumor destruction in mice and
humans with large, established cancers
(Gattinoni et al., 2006).
One scenario for how oncogene addic-
tion might be linked to immune eradica-
tion is illustrated in Figure 1D. It seems10 Elsevier Inc.plausible that removal of a single onco-
gene might start the process of tumor
cell death by a cell-intrinsic mechanism,
thereby releasing tumor-associated anti-
gens and immune modulators that acti-
vate antigen presenting cells (APC). The
MHC class II pathway, which presents
antigens to CD4+ T cells, is particularly
efficient at processing extracellular anti-
gens (Muranski and Restifo, 2009). The
mechanism of tumor cell death resulting
in antigen presentation and immune
activation is similar in many ways to
the tumor immunogenicity that can be
induced after the use of some chemother-
apies (Zitvogel et al., 2008).
These results call for more study of the
mechanisms of tumor regression after
oncogene withdrawal using immunologi-
cally intact animals but point to areas of
concern as well. The tumors studied by
Rakhra et al. in this report may represent
highly immunogenic variants because
they are engineered to express the immu-
nologically ‘‘foreign’’ proteins of the Tet
regulatory protein and inducible human
MYC protein. In addition, the authors may
have inadvertently increased the immuno-
genicity of the transplanted tumors by
inserting the luciferase enzyme, which
might itself function as a ‘‘non-self’’ pro-
tein. Tumor immunologists might view
insertion of this artificial genetic informa-
tion as something akin to introduction of
a foreign protein such as chicken oval-
bumin into a tumor, which dramatically
increases its immunogenicity. The artifi-
cial aspects of this sort of immunity might
not translate well into human trials, where
there is ample time for the immune system
to become activated and select against
highly immunogenic tumor-associated
epitopes. In addition, human trials of
molecular targeted therapies do not thus
far hint at having a strong immune-
activating component, where expected
immune-type side effects would likely
include fevers, headaches, myalgias, and
even hypotension.
In conclusion, the fields of molecular
targeted therapy and immunotherapy of
cancer still seem worlds apart, but addi-
tional experiments are clearly warranted.
The use of animal models with intact
host immune systems could enable the
study of potential combination therapies.
Thomas Henry Huxley wrote how in
science ‘‘many a beautiful theory [is] killed
by an ugly fact.’’ To accurately determine
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Previewsthe fate of combination therapies using
molecular targeted therapies together
with immune-based manipulations, future
experiments should be performed using
spontaneous tumors in the nontransplan-
tation setting or tumor systems with less
intrinsic immunogenicity. Such combina-
tions may enable the more frequent
induction of long-term durable cancer
regression.ACKNOWLEDGMENTS
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The biological basis of the phenotypic diversity observed in JAK2V617F-positive myeloproliferative
neoplasms is poorly understood. In this issue of Cancer Cell, Chen et al. show that interferon and STAT1
signaling are activated in essential thrombocythemia but not in polycythemia vera. STAT1 promotes mega-
karyopoiesis and thus contributes to an essential thrombocythemia phenotype.Myeloproliferative neoplasms (MPN) are
clonal disorders of hematopoiesis and
are characterized by an accumulation
of mature blood cells. The JAK2V617F-
activating mutation is the most common
molecular abnormality in BCR-ABL-
negative MPN and is present in approxi-
mately 95% of patients with poly-
cythemia vera (PV) and approximately
50% of patients with essential thrombo-
cythemia (ET) and myelofibrosis (Levine
andGilliland, 2008). JAK2 is a cytoplasmic
tyrosine kinase that mediates intracellular
signaling between cell-surface cytokine
receptors and multiple downstream
effector pathways. The V617F mutation
is located in the negative regulatory pseu-
dokinase domain of JAK2 and results in
ligand-independent activation of JAK2
signaling and activation of STAT5 tran-scription (James et al., 2005). JAK2 was
recently found to phosphorylate Tyr41
(Y41) on histone H3 and thus lead to
the release of transcriptional repression
from heterochromatin protein 1a (HP1a)
(Dawson et al., 2009).
In this issue of Cancer Cell, Chen et al.
(Chen et al., 2010) examine how the
JAK2V617Fmutation can lead to different
diseases, PV and ET, with distinct clinical
features. In part, PV is molecularly distinct
from ET because of a higher JAK2V617F
mutational burden in PV patients. Mitotic
recombination of the distal part of chro-
mosome 9p occurs in approximately
one third of PV patients and results in
JAK2V617F homozygosity, whereas mi-
totic recombination almost never occurs
in ET patients (Kralovics et al., 2005).
Chen et al. therefore focused onJAK2V617F heterozygous cells by com-
paring the transcriptional profiles of
erythroid progenitors from patients with
PV or ET to gain insight into the molecular
differences in these diseases.
A key feature of this study is the use
of clonally derived cells for molecular
studies to overcome several technical
challenges in the study of gene expression
in MPN patients and in cancer samples
more generally. The analysis of gene
expression in MPN can be confounded
by the effects of an aberrant micro-
environment, variation in endogenous
cytokine levels, different JAK2V617F
mutational burdens between samples,
genetic heterogeneity within a sample,
and skewing of the differentiation state
within a population of cells in a sample.
Chen et al. addressed these challengesovember 16, 2010 ª2010 Elsevier Inc. 405
